Institute of Human Virology Vaccine Research Trial
This is a Phase 1 clinical trial designed to evaluate the safety and immunogenicity of a HIV vaccine called FLSC (full-length single chain) in healthy volunteers without HIV infection. This novel vaccine was developed by investigators at the Institute of Human Virology as a potential future strategy to help prevent HIV infection.
Volunteers must be healthy, between 18-45 years of age, HIV negative, and have never previously participated in an HIV or DNA vaccine trial. Compensation given for travel and expenses.
If you are interested in learning more about this program, please contact Joyce Lam 410-706-3367.
Institute of Human Virology
Clinical Research Unit
725 W. Lombard St.
Baltimore, MD 21201